- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05256797
Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data
July 25, 2023 updated by: Shirley Vichy Wang, Brigham and Women's Hospital
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical School.
It is intended to replicate, as closely as possible in healthcare insurance claims data, the trial listed below/above.
Although many features of the trial cannot be directly replicated in healthcare claims, key design features, including outcomes, exposures, and inclusion/exclusion criteria, were selected to proxy those features from the trial.
Randomization is also not replicable in healthcare claims data but was proxied through a statistical balancing of measured covariates through standard practice.
Investigators assume that the RCT provides the reference standard treatment effect estimate and that failure to replicate RCT findings is indicative of the inadequacy of the healthcare claims data for replication for a range of possible reasons and does not provide information on the validity of the original RCT finding.
Study Type
Observational
Enrollment (Actual)
529536
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02120
- Brigham and Women's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
This study will involve a new user, parallel group, propensity score-matched, retrospective cohort study design comparing rivaroxaban to apixaban users.
The patients will be required to have continuous enrollment during a baseline period of 180 days before initiation of rivaroxaban or apixaban (index date).
Analysis is restricted to patients with non-valvular atrial fibrillation.
Description
Inclusion Criteria:
- At least 18 years of age
- Non-valvular atrial fibrillation
Exclusion Criteria:
- Prior anticoagulant use [Day -180, Day 0]
- Stage 4 or 5 chronic kidney disease or end-stage renal disease [Day -180, Day 0]
- Dialysis or renal transplant [Day -180, Day 0]
- Recent major or clinically relevant non-major bleeding [Day -180, Day 0]
- Other indications for anticoagulation (DVT, PE, or prosthetic heart valve) [Day -180, Day 0]
- Use of an antiplatelet [Day -180, Day 0]
- Significant liver disease and coagulopathy [Day -180, Day 0]
- Use of CYP3A4 or P-gp inhibitors or inducers [Day -180, Day 0]
- Pregnancy or breastfeeding [Day -180, Day 0]
- Cancer [Day -180, Day 0]
- Bypass surgery, obesity, or the use of a weight loss or appetite suppressor [Day -180, Day 0]
- Mitral stenosis with or without insufficiency, mitral rheumatic insufficiency, and other/unspecified mitral valve disorders [Day -180, Day 0]
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Rivaroxaban
Reference group
|
Any rivaroxaban dispensing claim is used as the reference group
Other Names:
|
Apixaban
Exposure group
|
Any apixaban dispensing claim is used as the exposure group
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative hazard of major bleeding or clinically relevant non-major bleeding events
Time Frame: Through study completion or censoring, up to 365 days
|
Claims-based algorithm: relative hazard of major bleeding or clinically relevant non-major bleeding events
|
Through study completion or censoring, up to 365 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative hazard of major bleeding
Time Frame: Through study completion or censoring, up to 365 days
|
Claims-based algorithm: relative hazard of major bleeding
|
Through study completion or censoring, up to 365 days
|
Relative hazard of clinically relevant non-major bleeding
Time Frame: Through study completion or censoring, up to 365 days
|
Claims-based algorithm: relative hazard of clinically relevant non-major bleeding
|
Through study completion or censoring, up to 365 days
|
Relative hazard of all-cause mortality
Time Frame: Through study completion or censoring, up to 365 days
|
Claims-based algorithm: relative hazard of all-cause mortality
|
Through study completion or censoring, up to 365 days
|
Relative hazard of stroke
Time Frame: Through study completion or censoring, up to 365 days
|
Claims-based algorithm: stroke
|
Through study completion or censoring, up to 365 days
|
Relative hazard of extracranial bleeding
Time Frame: Through study completion or censoring, up to 365 days
|
Claims-based algorithm: relative hazard of extracranial bleeding
|
Through study completion or censoring, up to 365 days
|
Relative hazard of intracranial bleeding
Time Frame: Through study completion or censoring, up to 365 days
|
Claims-based algorithm: relative hazard of intracranial bleeding
|
Through study completion or censoring, up to 365 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Shirley Wang, PhD, ScM, Brigham and Women's Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 3, 2021
Primary Completion (Actual)
June 15, 2022
Study Completion (Actual)
June 15, 2022
Study Registration Dates
First Submitted
February 16, 2022
First Submitted That Met QC Criteria
February 16, 2022
First Posted (Actual)
February 25, 2022
Study Record Updates
Last Update Posted (Actual)
July 27, 2023
Last Update Submitted That Met QC Criteria
July 25, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018P002966-DUP-COBRRA-AF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
Abbott Medical DevicesRecruitingAtrial Fibrillation | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited States, Australia, Belgium, Germany, Spain, Netherlands, France, Austria, Canada, Czechia, Italy, United Kingdom
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
Clinical Trials on Rivaroxaban
-
Portola PharmaceuticalsCompleted
-
Korea University Anam HospitalRecruitingAtrial Fibrillation | Anticoagulant Adverse ReactionKorea, Republic of
-
Doasense GmbHActive, not recruitingAnticoagulant TherapyGermany
-
China National Center for Cardiovascular DiseasesNot yet recruitingStroke | Atrial Fibrillation | Major Adverse Cardiac Events | Anticoagulant Adverse Reaction
-
BayerCompleted
-
The Affiliated Hospital of Qingdao UniversityCompletedHealthy SubjectsChina
-
BayerJanssen R&D, L.L.C.Completed
-
BayerJanssen Research & Development, LLCCompletedCoronary Artery Disease | Cardiovascular DiseaseBelgium, Netherlands
-
University Hospital, GrenobleCompleted
-
Addpharma Inc.CompletedEmbolism and ThrombosisKorea, Republic of